This site is intended for healthcare professionals only
Case studies
Share this article

This interactive case study, presented by Diabetes & Primary Care, takes you through the necessary considerations in managing diabetic nephropathy in an individual with type 2 diabetes. The scenario is not unusual and is one that, as a primary healthcare worker, you could easily be confronted with. By actively engaging with this case history, you should feel more confident and empowered to manage effectively such a problem in the future.

  1. Buse JB, Wexler DJ, Tsapas A et al (2020) 2019 Update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD). Diabetes Care 43: 487–93
  2. NICE (2014) Chronic kidney disease in adults: assessment and management (CG182). Available at: (accessed 07.12.20)
  3. Winocour P, Diggle J, Davies S et al (2020) Testing for kidney disease in type 2 diabetes: consensus statement and recommendations. Diabetes & Primary Care 22: 99–109
  4. He F, Xia X, Wu XF et al (2013) Diabetic retinopathy in predicting diabetic nephropathy in patients with type 2 diabetes and renal disease: a meta-analysis. Diabetologia 56: 457–66
  5. Pradeepa R, Anjana RM, Unnikrishnan R et al (2010) Risk factors for microvascular complications of diabetes among South Indian subjects with type 2 diabetes – the Chennai Urban Rural Epidemiology Study (CURES) Eye Study-5. Diabetes Technol Ther 12: 755–61
  6. Ninomiya T, Perkovic V, de Galan BE et al (2009) Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 20: 1813–21
  7. Toyama T, Furuichi K, Ninomiya T et al (2013) The impacts of albuminuria and low eGFR on the risk of cardiovascular death, all-cause mortality, and renal events in diabetic patients: meta-analysis. PLoS One 8: e71810
  8. Saran R, Robinson B, Abbott KC et al (2017) US Renal Data System 2016 Annual Data Report. Am J Kidney Dis 69(Suppl 1): S1–688
  9. Bilous R (2016) Diabetic nephropathy. Diagnosis, screening and management. Diabetes & Primary Care 18: 38–46
  10. Ruospo M, Saglimbene VM, Palmer SC et al (2017) Glucose targets for preventing diabetic kidney disease and its progression. Cochrane Database Syst Rev 6: CD001037
  11. UKPDS Group (1998) Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in type 2 diabetes (UKPDS 33). Lancet 352: 837–53
  12. Wanner C, Inzucchi, Lachin M et al (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375: 323–34
  13. Neal B, Perkovic V, Mahaffery KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377: 644–57
  14. Wiviott SD, Raz I, Bonaca MP et al (2018) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380: 347–57
  15. Cannon CP, Pratley R, Dagogo-Jack S et al; VERTIS CV Investigators (2020) Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med 383: 1425–35
  16. Perkovic V, Jardine M, Neal B et al; CREDENCE Trial Investigators (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380: 2295–306
  17. Heerspink HJ, Stefansso BV, Corea-Rotter R et al; DAPA-CKD Trial Committees and Investigators (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383: 1436–46
  18. ADA (2021) 9. Pharmacological approaches to glycemic treatment: Standards of Medical Care in Diabetes–2021. Diabetes Care 44(Suppl 1): S111–24
  19. ADA (2021) 11. Microvascular complications and foot care: Standards of Medical Care in Diabetes–2021Diabetes Care 44(Suppl 1): S151–62
  20. Boer IH, Caromori ML, Chan JC et al (2020) Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: an evidence-based advances in monitoring and treatment. Kidney Int 98: 829–48
  21. (2020) Invokana 100 mg and 300 mg film-coated tablets (SmPC). Available at: (accessed 10.12.20)
  22. Kristensen SL, Rorth R, Jhund PS et al (2019) Cardiovascular, mortality and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes and Endocrinol 7: 776–85
  23. Deacon CF (2018) A review of dipeptidyl peptidase-4 inhibitors. Hot topics from randomised controlled trials. Diabetes Obes Metab 20(Suppl 1): 34–46
  24. Hirst J, Taylor K, Stevens R et al (2012) The impact of renin–angiotensin–aldosterone system inhibitors on type 1 and type 2 diabetic patients with and without nephropathy. Kidney Int 81: 674–83
  25. Palmer SC, Mauvidis SC, Navarese E et al (2015) Comparative efficacy and safety of blood-pressure lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet 385: 2047–56
  26. Fried L, Emanuele N, Zhang J et al (2013) Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 369: 1892–903
  27. NICE (2014) Cardiovascular disease: risk assessment and reduction including lipid modification (CG181). Available at: (accessed 07.12.20)
  28. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2020) KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int (Suppl 4): S1–115

Related content
Free for all UK & Ireland healthcare professionals

Sign up to all DiabetesontheNet journals


By clicking ‘Subscribe’, you are agreeing that are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.

Are you a healthcare professional? This website is for healthcare professionals only. To continue, please confirm that you are a healthcare professional below.

We use cookies responsibly to ensure that we give you the best experience on our website. If you continue without changing your browser settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies.